Respiratory and Pulmonary Medicine: Clinmed
Respiratory and Pulmonary Medicine: Clinmed
Respiratory and Pulmonary Medicine: Clinmed
*Corresponding author: Sonia Akter, Department of Microbiology, Dhaka Medical College, Dhaka, Bangladesh,
E-mail: soniaakterkhan83@gmail.com
or residing in a long term care facility for > 14 days before the onset
Abstract of symptoms [4]. Diagnosis depends on isolation of the infective
Community-acquired pneumonia (CAP) is typically caused by organism from sputum and blood. Knowledge of predominant
an infection but there are a number of other causes. The most microbial patterns in CAP constitutes the basis for initial decisions
common type of infectious agents is bacteria such as Streptococcus about empirical antimicrobial treatment [5].
pneumonia. CAP is defined as an acute infection of the pulmonary
parenchyma in a patient who has acquired the infection in the Microbial Pathogens
community. CAP remains a common and potentially serious illness.
It is associated with considerable morbidity, mortality and treatment Strep. pneumoniae accounted for over 80 percent of cases of
cost, particularly in elderly patients. CAP causes problems like community-acquired pneumonia in the era before penicillin [6].
difficulty in breathing, fever, chest pains, and cough. Definitive Strep. pneumoniae is still the single most common defined pathogen
clinical diagnosis should be based on X-ray finding and culture in nearly all studies of hospitalized adults with community-acquired
of lung aspirates. The chest radiograph is considered the” gold
pneumonia [7-9]. Other bacteria commonly encountered in cultures of
standard” for the diagnosis of pneumonia but cannot differentiate
bacterial from non bacterial pneumonia. Diagnosis depends
expectorated sputum are Haem. influenzae, Staph. aureus, and gram-
on isolation of the infective organism from sputum and blood. negative bacilli [10]. Less common agents are Moraxella catarrhalis,
Knowledge of predominant microbial patterns in CAP constitutes Strep. pyogenes, and Neisseria meningitides [11]. Anaerobic bacteria
the basis for initial decisions about empirical antimicrobial treatment. are the dominant pathogens in patients with aspiration pneumonia,
lung abscess, or empyema. Transtracheal-aspiration fluid indicated
Keywords that pneumonitis due to anaerobes cannot be distinguished clinically
Pneumonia, Community acquired pneumonia, Causative agents, from other common forms of bacterial pneumonia. The implications
Clinical features, Diagnosis, Antibiotics, Prevention are that anaerobes probably account for a substantial number of
enigmatic pneumonias and that the diagnostic techniques now in
common use cannot detect them [12,13].
Introduction
Legionella, Mycop. pneumoniae, and Chl. Pneumonia referred to
Pneumonia is defined as an acute respiratory illness associated as the “atypical agents,” collectively account for 10 to 20 percent of all
with recently developed radiological pulmonary shadowing which cases of pneumonia. All show great variations in frequency according
may be segmental, lobar or mutilobar [1]. It occurs about five times to the patient’s age and to temporal and geographic patterns. Legionella
more frequently in the developing world than the developed world is reported in 1 to 5 percent of hospitalized adults with community-
[2]. The incidence of community acquired pneumonia (CAP) range acquired pneumonia but geographic variation is substantial and
from 4 million to 5 million cases per year, with 25% requiring detection is problematic. Culture is probably the best method, but a
hospitalization [3]. The problem is much greater in the developing survey showed that 32 percent were unable to grow legionella even
countries where pneumonia is the most common cause of hospital from pure cultures, measurement of antigenuria is sensitive and easy,
attendance in adults. Pneumonia are usually classified as community but it is limited to L. pneumophila serogroup 1 (70 to 90 percent
acquired pneumonia, hospital acquired pneumonia or those of cases), and direct fluorescent-antibody staining of sputum often
occurring in immunocompromised host or patient with underlying considered unreliable for species other than L. pneumophila [14]. The
damaged lung including suppurative and aspiration pneumonia [1]. frequency of infection with Mycop. pneumoniae among hospitalized
adults with community-acquired pneumonia ranges from 1 percent
The Disease to 8 percent, and it is much higher for young adults who are treated
Community acquired pneumonia is commonly defined as an as outpatients. Diagnostic procedures include serologic tests, culture,
acute infection of the pulmonary parenchyma that is associated with and the polymerase chain reaction (PCR) [15]. Chl. pneumoniae
at least some symptoms of acute infection and is accompanied by the reportedly accounts for 5 to 10 percent of cases of community-
presence of an acute infiltrate on a chest radiograph or auscultatory acquired pneumonia. Diagnosis of this agent can be done by serologic
findings consistent with pneumonia (such as altered breath sounds testing, culture and by PCR [16].
and/or localized rales) and occurs in a patient who is not hospitalized
Viral agents account for 2 to 15 percent of cases, most commonly
CAP is a common illness and can affect people of all ages. CAP is Therapeutic decisions are greatly simplified if the infecting
usually spread by droplet infection and most cases occurs previously pathogen is known. In general, tests that provide immediate
healthy individual. Several factors can impair the effectiveness of local information are desirable such as Gram’s staining with or without the
quellung test, staining for acid-fast bacilli, direct fluorescent-antibody
defenses and predispose to CAP. Once the organism settles in the
tests for legionella, or PCR for Mycop. pneumoniae, Chl. pneumoniae,
alveoli, an inflammatory response ensues. The classical pathological
and Mycob. Tuberculosis [21]. In the absence of guidance from the
response evolves through the phases of congestion, red and grey
results of rapid diagnostic tests, recent guidelines for empirical
hepatisation and finally resolution with little or no scarring [1].
decision making are available from the British Thoracic Society and
In pneumonia, the lungs become filled with pus, and this makes the American Thoracic Society. These two groups reviewed similar
them stiff. So the patient breathes fast with stiff lungs. As pneumonia data and recommended quite different regimens. The conclusion
become worse, the lungs become even stiffer and they do not expand of the British Thoracic Society was that empirical therapy should
properly. Severe pneumonia has a lot of pus in their lungs, so their always cover Strep. pneumoniae. The preferred regimen is penicillin
lungs are very stiff. The sign on which estimation of severity of ALRI or amoxicillin; erythromycin should be given if legionella or Mycop.
is also depend on mediator of inflammation known as acute phase pneumonia is specifically suspected and antibiotics directed against
response [1,18]. Staph. aureus should be considered during epidemics of influenza.
The American Thoracic Society recommended the use of macrolides,
Laboratory Diagnosis second- and third-generation cephalosporins, trimethoprim–
sulfamethoxazole, and beta-lactam–beta-lactamase inhibitors. Agents
Chest x-ray
active against legionella, Mycop. pneumoniae, and Chl. pneumoniae
This is the cardinal investigation. In the appropriate setting, a new include new macrolides (clarithromycin and azithromycin), which
Akter et al. Int J Respir Pulm Med 2015, 2:2 ISSN: 2378-3516 • Page 2 of 5 •
are more expensive than erythromycin but better tolerated and • Doxycycline 100mg PO bid
more active against Haem. Influenzae [22]. About 30 percent of the
• If received prior antibiotic within 3 months:
strains of Haem. influenzae produce beta-lactamase and are resistant
to ampicillin; most are susceptible to cephalosporins, doxycycline, • Azithromycin or clarithromycin plus amoxicillin 1g PO q8h
and trimethoprim–sulfamethoxazole. Fluoroquinolones are effective or amoxicillin-clavulanate 2g PO q12h or
against atypical agents and Haem. Influenzae.
• Respiratory fluoroquinolone (eg, levofloxacin 750mg PO
The prevalence of penicillin-resistant Strep. pneumoniae, which daily or moxifloxacin 400mg PO daily)
accounts for over 25 percent of pneumococcal isolates in some
• Comorbidities present (eg, alcoholism, bronchiectasis/
areas of the United States and for higher rates in other areas of the
cystic fibrosis, COPD, IV drug user, post influenza, asplenia,
world [23-25]. Alternative drugs are limited because of resistance to
diabetes mellitus, lung/liver/renal diseases):
trimethoprim–sulfamethoxazole, macrolides, and cephalosporins.
Most strains have intermediate resistance to penicillin, and • Levofloxacin 750mg PO q24h or
uncomplicated pneumonia caused by these strains may be treated with
• Moxifloxacin 400mg PO q24h or
high doses of penicillin or selected cephalosporins, such as cefaclor
or cefotaxime [24]. Mortality due to pneumococcal pneumonia Combination of a beta-lactam (amoxicillin 1g PO q8h or
involving resistant strains is similar to that for pneumonia involving amoxicillin-clavulanate 2g PO q12h or ceftriaxone 1g IV/IM q24h
sensitive strains, even when the treatment includes penicillins or or cefuroxime 500mg PO BID) plus a macrolide (azithromycin or
cephalosporins [25]. clarithromycin)
Most patients with no bacteriologic diagnosis have infections Duration of therapy: minimum of 5 days, should be afebrile for
involving atypical agents such as legionella species, Mycop. 48-72 hours, or until afebrile for 3 days; longer duration of therapy
pneumoniae, or Chl. pneumoniae. This assumption accounts for may be needed if initial therapy was not active against the identified
the frequent use of macrolides for pneumonia, although studies in pathogen or if it was complicated by extrapulmonary infections.
outpatients show that macrolides and beta-lactam agents are equally Inpatient, non-ICU:
effective in adult outpatients with pneumonia [26]. Legionella is
an important pulmonary pathogen that requires treatment with • Levofloxacin 750mg IV or PO q24h or
a macrolide or fluoroquinolone, and applies only to hospitalized • Moxifloxacin 400mg IV or PO q24h or
patients [27].
• Combination of a beta-lactam (ceftriaxone 1g IV q24h or
Adults with community-acquired pneumonia should receive cefotaxime 1g IV q8h or ertapenem 1g IV daily or ceftaroline
treatment with antibiotic agents selected according to the results 600mg IV q12h) plus azithromycin 500mg IV q24h
of microbiologic studies of sputum and blood cultures. For young
adults treated as outpatients, the oral administration of a macrolide • Duration of therapy: minimum of 5 days, should be afebrile for
(erythromycin, clarithromycin, or azithromycin) or doxycycline; 48-72 hours, stable blood pressure, adequate oral intake, and
for patients older than 25, oral amoxicillin or an oral cephalosporin room air oxygen saturation of greater than 90%; longer duration
is also acceptable. For adults over 60 and those with coexisting may be needed in some cases.
illnesses who are treated as outpatients: oral cephalosporin or Inpatient, ICU:
amoxicillin; for patients with penicillin allergy, oral macrolide or
doxycycline. For hospitalized patients: Second- or third-generation Severe COPD:
cephalosporin (cefuroxime, cefotaxime, or ceftriaxone) with or • Levofloxacin 750mg IV or PO q24h or
without erythromycin, given parenterally; parenteral therapy should
continue until the patient has been afebrile for more than 24 hours • Moxifloxacin 400mg IV or PO q24h or
and oxygen saturation exceeds 95 percent [28]. • Ceftriaxone 1g IV q24h or ertapenem 1g IV q24h plus
Several medical-specialty professional societies have suggested azithromycin 500mg IV q24h
that combination therapy with a β-lactam plus a macrolide or If gram-negative rod pneumonia (Pseudomonas) suspected, due
doxycycline or monotherapy with a “respiratory quinolone” (i.e., to alcoholism with necrotizing pneumoniae, chronic bronchiectasis/
levofloxacin, gatifloxacin, moxifloxacin, or gemifloxacin) are optimal tracheobronchitis due to cystic fibrosis, mechanical ventilation,
first-line therapy for patients hospitalized with community-acquired febrile neutropenia with pulmonary infiltrate, septic shock with
pneumonia [29]. Combination antibiotic therapy achieves a better organ failure:
outcome compared with monotherapy, and it should be given in the
following subset of patients with CAP: outpatients with comorbidities • Piperacillin-tazobactam 4.5g IV q6h or 3.375g IV q4h or 4-h
and previous antibiotic therapy, nursing home patients with CAP, infusion of 3.375g q8h or
hospitalized patients with severe CAP, bacteremic pneumococcal • Cefepime 2g IV q12h or
CAP, presence of shock, and necessity of mechanical ventilation [30].
• Imipenem/cilastatin 500mg IV q6h or meropenem 1 g IV q8h or
Empiric therapeutic regimens for CAP are outlined below,
including those for outpatients with or without comorbidities, • If penicillin allergic, substitute aztreonam 2g IV q6h plus
intensive care unit (ICU) and non-ICU patients, and penicillin- • Levofloxacin 750mg IV q24h or
allergic patients [31].
• Moxifloxacin 400mg IV or PO q24h or
Outpatient:
• Aminoglycoside (gentamicin 7mg/kg/day IV or tobramycin 7mg/
• No comorbidities/previously healthy; no risk factors for kg/day IV)
drug-resistant S pneumoniae:
• Add azithromycin 500mg IV q24h if respiratory fluoroquinolone
• Azithromycin 500mg PO one dose, then 250mg PO daily for not used
4 d or extended-release 2g PO as a single dose
Duration of therapy: 10-14 days
or
If concomitant with or post influenza:
• Clarithromycin 500mg PO bid or extended-release 1000mg
PO q24h or • Vancomycin 15mg/kg IV q12h or linezolid 600 mg IV bid plus
Akter et al. Int J Respir Pulm Med 2015, 2:2 ISSN: 2378-3516 • Page 3 of 5 •
• Levofloxacin 750mg IV q24h or who do not have a spleen. A repeat vaccination may also be required
after five or ten years [35].
• Moxifloxacin 400mg IV or PO q24h
Influenza vaccines should be given yearly to the same individuals
• If received prior antibiotic within 3 months:
as receive vaccination against Streptococcus pneumoniae. In addition,
• High-dose ampicillin 2g IV q6h (or penicillin G, if not resistant); health care workers, nursing home residents, and pregnant women
if penicillin allergic, substitute with vancomycin 1g IV q12h plus should receive the vaccine. When an influenza outbreak is occurring,
medications such as amantadine, remantadine, zanamivir and
• Azithromycin 500mg IV q24h plus oseltamivir have been shown to prevent causes of influenza [36].
• Levofloxacin 750mg IV q24h or moxifloxacin 400mg IV/PO q24h
Conclusion
• Risk of aspiration pneumonia/anaerobic lung infection/lung
abscess: Prevention of pneumonia is obviously an important goal.
Infection with influenza is a critical factor, especially in elderly
• Clindamycin 300-450mg PO q8h or patients who constitute the adult population group with the highest
• Ampicillin-sulbactam 3g IV q6h or attack rate for community-acquired pneumonia and the group with
the highest mortality due to the disease. Strep. pneumoniae continues
• Ertapenem 1g IV q24h or to be the most common bacterial pathogen in most of the studies of
pneumonia and has aroused concern because of the dramatic increase
• Ceftriaxone 1g IV q24h plus metronidazole 500mg IV q6h or
in the rates of resistance to antibacterial agents among isolates. So, we
• Moxifloxacin 400mg IV or PO q24h or should concern about the current guidelines for the judicious use of
antimicrobial agents.
• Piperacillin-tazobactam 3.375g IV q6h or
• If methicillin-resistant S aureus (MRSA) is suspected, add
vancomycin 15mg/kg IV q12h or linezolid 600mg IV/PO q12h References
1. Reid PT, Innes JA (2010) Respiratory Disease. In: Colledge NR, Walker BR
• If influenza is suspected, add oseltamivir 75mg IV or PO q12h and Ralston SH, ed, Davidson’s principle and practice of Medicine, 21sted.
for 5d Edinburgh: Elsevier publications. 680-682.
Oral fluoroquinolones (ciprofloxacin and ofloxacin) are acceptable 2. Ruuskanen O, Lahti E, Jennings LC, Murdoch DR (2011) Viral pneumonia.
Lancet 377: 1264-1275.
alternatives to macrolides for legionnaires’ disease, and for Mycop.
pneumoniae and Chl. pneumoniae as well. In areas with high rates 3. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, et al. (2003)
Update of practice guidelines for the management of community-acquired
of resistance strains of Strep. pneumoniae, local sensitivity patterns pneumonia in immunocompetent adults. Clin Infect Dis 37: 1405-1433.
should be taken into account. The duration of therapy is 5 to 10 days
is usually advocated for common bacterial pneumonias, 10 to 14 days 4. Bartlett JG, Breiman RF, Mandell LA, File TM Jr (1998) Community-acquired
pneumonia in adults: guidelines for management. The Infectious Diseases
for those caused by Mycop. pneumoniae or Chl. pneumoniae, and 14 Society of America. Clin Infect Dis 26: 811-838.
to 21 days for legionnaires’ disease [22]. Criteria for defining failure
5. Woodhead M, Blasi F, Ewig S, Huchon G, Leven M, et al. (2005) European
to respond are not readily available, although previously healthy society of clinical microbiology and infectious diseases. Guidelines for the
adults with pneumococcal pneumonia are usually afebrile within management of adult lower respiratory tract infections. Eur Respir J 26: 1138-
three days [32]. Older patients with pneumococcal pneumonia or 1180.
bacteremic pneumococcal pneumonia and pneumonia due to gram- 6. Bullowa JGM (1935) The reliability of sputum typing and its relation to serum
negative bacilli, Staph. aureus, or legionella usually respond more therapy. JAMA 105: 1512-1518.
slowly. Radiographic changes are slow in comparison with the clinical 7. Janssen RS, St Louis ME, Satten GA, Critchley SE, Petersen LR, et al. (1992)
response. Microbiologic tests for common bacterial pathogens in HIV infection among patients in U.S. acute care hospitals. Strategies for the
patients with poor responses are generally considered unreliable after counseling and testing of the hospital patients. The Hospital HIV Surveillance
Group. N Engl J Med 327: 445-452.
antibiotics have been given. Fiberoptic bronchoscopy is often useful
for the detection of underlying lesions such as neoplasms, for the 8. (1987) Community-acquired pneumonia in adults in British hospitals in 1982-
detection of selected pathogens such as Mycob. tuberculosis, P. carinii, 1983: a survey of aetiology, mortality, prognostic factors and outcome. The
British Thoracic Society and the Public Health Laboratory Service. Q J Med
or pathogenic fungi, and occasionally for the detection of Staph. aureus 62: 195-220.
or gram-negative bacilli, if quantitative cultures are performed [33].
9. Lim I1 Shaw DR, Stanley DP, Lumb R, McLennan G (1989) A prospective
A computed tomographic scan may identify undetected anatomical hospital study of the aetiology of community-acquired pneumonia. Med J Aust
changes. Follow-up chest films are most justified for patients with 151: 87-91.
a delayed response, an uncertain cause of pneumonia, or infection 10. Akter S, Shamsuzzaman SM and Jahan F (2014) Community acquired
with penicillin-resistant Strep. pneumoniae. Long-term follow-up bacterial pneumonia: aetiology, laboratory detection and antibiotic
radiography is indicated for patients who have delayed responses, for susceptibility pattern. Malaysian J Pathol 36: 97-103.
those who may have bronchogenic neoplasms or other underlying 11. Bartlett JG (1979) Anaerobic bacterial pneumonitis. Am Rev Respir Dis 119:
disease, and for those with recurrent pneumonia [34]. 19-23.
Akter et al. Int J Respir Pulm Med 2015, 2:2 ISSN: 2378-3516 • Page 4 of 5 •
18. Kalinske RW, Parker RH, Brandt D, Hoeprich PD (1967) Diagnostic usefulness 27. Bohte R, van’t Wout JW, Lobatto S, Blussé van Oud Alblas A, Boekhout M,
and safety of transtracheal aspiration. N Engl J Med 276: 604-608. et al. (1995) Efficacy and safety of azithromycin versus benzylpenicillin or
erythromycin in community-acquired pneumonia. Eur J Clin Microbiol Infect
19. Mandell LA, Marrie TJ, Grossman RF (2003) Summary of Canadian Dis 14: 182-187.
Guidelines for the Initial Management of Community-acquired Pneumonia:
An evidence-based update by the Canadian Infectious Disease Society and 28. Marrie TJ (1994) Community-acquired pneumonia. Clin Infect Dis 18: 501-
the Canadian Thoracic Society. Clin Infect Dis 31: 383-421. 513.
20. Yang S, Lin S, Khalil A, Gaydos C, Nuemberger E, et al. (2005) Quantitative 29. Martinez FJ (2004) Monotherapy versus dual therapy for community-acquired
PCR assay using sputum samples for rapid diagnosis of pneumococcal pneumonia in hospitalized patients. Clin Infect Dis 38 Suppl 4: S328-340.
pneumonia in adult emergency department patients. J Clin Microbiol 43:
3221-3226. 30. Caballero J, Rello J (2011) Combination antibiotic therapy for community-
acquired pneumonia. Ann Intensive Care 1: 48.
21. The British Thoracic Society (1993) Guidelines for the management of
community-acquired pneumonia in adults admitted to hospital. Br J Hosp 31. Mandell GL, Bennett GE, Dolin R (2010) Acute Pneumonia. In: Principles and
Med 49: 346-350. Practice of Infectious Diseases. Vol 1. (7th edn). Philadelphia, Pa: Churchill
Livingstone 904.
22. Niederman MS, Bass JB Jr, Campbell GD, Fein AM, Grossman RF, et al.
(1993) Guidelines for the initial management of adults with community- 32. Austrian R, Winston AL (1956) The efficacy of penicillin V (phenoxymethyl-
acquired pneumonia: diagnosis, assessment of severity, and initial penicillin) in the treatment of mild and of moderately severe pneumococcal
antimicrobial therapy. American Thoracic Society. Medical Section of the pneumonia. Am J Med Sci 232: 624-628.
American Lung Association. Am Rev Respir Dis 148: 1418-1426. 33. Feinsilver SH, Fein AM, Niederman MS, Schultz DE, Faegenburg DH (1990)
23. Austrian R (1994) Confronting drug-resistant pneumococci. Ann Intern Med Utility of fiberoptic bronchoscopy in nonresolving pneumonia. Chest 98: 1322-
121: 807-809. 1326.
24. Hofmann J, Cetron MS, Farley MM, Baughman WS, Facklam RR, et al. 34. Jay SJ, Johanson WG Jr, Pierce AK (1975) The radiographic resolution of
(1995) The prevalence of drug-resistant Streptococcus pneumoniae in Streptococcus pneumoniae pneumonia. N Engl J Med 293: 798-801.
Atlanta. N Engl J Med 333: 481-486. 35. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, et al. (1993)
25. Pallares R, Liñares J, Vadillo M, Cabellos C, Manresa F, et al. (1995) Pneumococcal polysaccharide vaccine efficacy. An evaluation of current
Resistance to penicillin and cephalosporin and mortality from severe recommendations. JAMA 270: 1826-1831.
pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 333: 474-480. 36. Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, et al. (1999) Use of
26. Kinasewitz G, Wood RG (1991) Azithromycin versus cefaclor in the treatment the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N
of acute bacterial pneumonia. Eur J Clin Microbiol Infect Dis 10: 872-877. Engl J Med 341: 1336-1343.
Akter et al. Int J Respir Pulm Med 2015, 2:2 ISSN: 2378-3516 • Page 5 of 5 •